@article{6f1f958870174ca58f2c3cf8c593a1e3,
title = "Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease",
abstract = "Alzheimer's disease (AD) is the most common neurodegenerative disorder and one of the leading causes of disability worldwide. The apolipoprotein E4 gene (APOE4) is the strongest genetic risk factor for AD. In 2023, the APOE4 National Institute on Aging/Alzheimer's Disease Sequencing Project working group came together to gather data and discuss the question of whether to reduce or increase APOE4 as a therapeutic intervention for AD. It was the unanimous consensus that cumulative data from multiple studies in humans and animal models support that lowering APOE4 should be a target for therapeutic approaches for APOE4 carriers. ANN NEUROL 2024;95:625–634.",
author = "Vance, {Jeffery M.} and Farrer, {Lindsay A.} and Yadong Huang and Carlos Cruchaga and Hyman, {Bradley T.} and Pericak-Vance, {Margaret A.} and Goate, {Alison M.} and Greicius, {Michael D.} and Griswold, {Anthony J.} and Haines, {Jonathan L.} and Julia Tcw and Schellenberg, {Gerard D.} and Tsai, {Li Huei} and Joachim Herz and Holtzman, {David M.}",
note = "Publisher Copyright: {\textcopyright} 2024 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.",
year = "2024",
month = apr,
doi = "10.1002/ana.26864",
language = "English",
volume = "95",
pages = "625--634",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley & Sons Inc.",
number = "4",
}